Evaluation of the safety and neuroprotective properties of the VCP inhibitor ML240 in large-animal and human retinal explants: a preclinical ex vivo investigation - Scorecard - MDSpire
Advertisement
Evaluation of the safety and neuroprotective properties of the VCP inhibitor ML240 in large-animal and human retinal explants: a preclinical ex vivo investigation
Clinical Scorecard: Evaluation of the safety and neuroprotective properties of the VCP inhibitor ML240 in large-animal and human retinal explants: a preclinical ex vivo investigation
At a Glance
Category
Detail
Condition
Retinal degenerative diseases
Key Mechanisms
Inhibition of valosin-containing protein (VCP) to preserve photoreceptor structure and function
Target Population
Patients with inherited retinal diseases (IRDs)
Care Setting
Preclinical research using organotypic retinal explants
Key Highlights
ML240 shows a comprehensive preclinical safety profile across species.
Retinal explants from pigs, macaques, and humans were used for evaluation.
ML240 was tested both as a free compound and in nanoparticle form.
The study supports ML240 as a mutation-independent therapeutic candidate.
Guideline-Based Recommendations
Diagnosis
Utilize organotypic retinal explants for safety and efficacy assessments.
Management
Consider ML240 for therapeutic development in retinal degenerative diseases.
Monitoring & Follow-up
Assess photoreceptor viability and microglial reactivity in explants.
Risks
Monitor for potential toxicity associated with VCP inhibition.
Patient & Prescribing Data
Individuals diagnosed with inherited retinal diseases (IRDs)
ML240 may provide neuroprotective effects without the toxicity seen in traditional models.
Clinical Best Practices
Incorporate large-animal and human-derived models in preclinical studies.
Evaluate drug delivery strategies to enhance efficacy and reduce toxicity.
At the Focus A-Eye Summit, in the session “Lessons from Formula One: Optimizing Clinical Workflow with AI,” experts examined how artificial intelligence can streamline and accelerate ophthalmic clinical workflows.
The combination of photodynamic therapy and intravitreal aflibercept did not improve 1-year visual acuity outcomes compared with aflibercept monotherapy.
